JP2020531531A5 - - Google Patents
Info
- Publication number
- JP2020531531A5 JP2020531531A5 JP2020511371A JP2020511371A JP2020531531A5 JP 2020531531 A5 JP2020531531 A5 JP 2020531531A5 JP 2020511371 A JP2020511371 A JP 2020511371A JP 2020511371 A JP2020511371 A JP 2020511371A JP 2020531531 A5 JP2020531531 A5 JP 2020531531A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- alkyl
- group
- trisubstituted
- disubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187101 | 2017-08-21 | ||
| EP17187101.5 | 2017-08-21 | ||
| PCT/EP2018/072398 WO2019038215A1 (en) | 2017-08-21 | 2018-08-20 | BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531531A JP2020531531A (ja) | 2020-11-05 |
| JP2020531531A5 true JP2020531531A5 (enExample) | 2023-02-02 |
| JP7287952B2 JP7287952B2 (ja) | 2023-06-06 |
Family
ID=59677148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511371A Active JP7287952B2 (ja) | 2017-08-21 | 2018-08-20 | アデノシン受容体アンタゴニストとしてのベンズイミダゾール誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11453647B2 (enExample) |
| EP (1) | EP3672952B1 (enExample) |
| JP (1) | JP7287952B2 (enExample) |
| KR (1) | KR20200043433A (enExample) |
| CN (1) | CN110997662B (enExample) |
| AU (1) | AU2018320673B2 (enExample) |
| BR (1) | BR112020003594A2 (enExample) |
| CA (1) | CA3073333A1 (enExample) |
| ES (1) | ES2940408T3 (enExample) |
| IL (1) | IL272637B2 (enExample) |
| SG (1) | SG11202001337XA (enExample) |
| TW (1) | TWI791593B (enExample) |
| WO (1) | WO2019038215A1 (enExample) |
| ZA (1) | ZA202001780B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3746124A4 (en) | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| WO2021155264A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155262A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| WO2022164135A1 (ko) * | 2021-01-29 | 2022-08-04 | 한국화학연구원 | 벤조티아졸 및 벤즈이미다졸 유도체, 약제학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| EP4351640A1 (en) | 2021-06-07 | 2024-04-17 | Ares Trading S.A. | Combination treatment of cancer |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| WO2024235218A1 (zh) * | 2023-05-15 | 2024-11-21 | 微境生物医药科技(上海)有限公司 | Hdac1/2选择性抑制剂及其用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4207554A (en) | 1972-08-04 | 1980-06-10 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
| US4125828A (en) | 1972-08-04 | 1978-11-14 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| US6579868B1 (en) | 1998-01-05 | 2003-06-17 | Eisai Co., Ltd. | Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| WO2001002400A1 (en) | 1999-07-02 | 2001-01-11 | Eisai Co., Ltd. | Fused imidazole compounds and remedies for diabetes mellitus |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| JP2005516917A (ja) | 2001-12-12 | 2005-06-09 | アメリカ合衆国 | 細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法 |
| WO2004092171A2 (en) | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists |
| WO2004101558A1 (en) | 2003-05-13 | 2004-11-25 | F. Hoffmann-La Roche Ag | 2-imidazo-benzothiazoles as adenosine receptor ligands |
| ATE389652T1 (de) * | 2003-05-19 | 2008-04-15 | Hoffmann La Roche | Benzothiazol-derivate als liganden des adenosinrezeptors |
| EP1628662B1 (en) | 2003-05-21 | 2007-02-14 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor |
| WO2005028484A1 (en) | 2003-09-19 | 2005-03-31 | F. Hoffmann-La Roche Ag | Thiazolopyridine derivatives as adenosine receptor ligands |
| AU2005247567B2 (en) * | 2004-05-24 | 2010-09-02 | F. Hoffmann-La Roche Ag | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |
| AU2005263500B2 (en) | 2004-07-22 | 2011-02-24 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
| US20060223849A1 (en) * | 2005-03-14 | 2006-10-05 | Mjalli Adnan M | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors |
| CN102731488A (zh) * | 2011-04-02 | 2012-10-17 | 中国医学科学院药物研究所 | 苯并咪唑类衍生物、及其制法和药物组合物与用途 |
-
2018
- 2018-08-20 KR KR1020207007994A patent/KR20200043433A/ko not_active Ceased
- 2018-08-20 ES ES18753209T patent/ES2940408T3/es active Active
- 2018-08-20 JP JP2020511371A patent/JP7287952B2/ja active Active
- 2018-08-20 US US16/640,490 patent/US11453647B2/en active Active
- 2018-08-20 TW TW107128915A patent/TWI791593B/zh not_active IP Right Cessation
- 2018-08-20 EP EP18753209.8A patent/EP3672952B1/en active Active
- 2018-08-20 WO PCT/EP2018/072398 patent/WO2019038215A1/en not_active Ceased
- 2018-08-20 IL IL272637A patent/IL272637B2/en unknown
- 2018-08-20 SG SG11202001337XA patent/SG11202001337XA/en unknown
- 2018-08-20 AU AU2018320673A patent/AU2018320673B2/en not_active Ceased
- 2018-08-20 BR BR112020003594-7A patent/BR112020003594A2/pt not_active Application Discontinuation
- 2018-08-20 CN CN201880054520.7A patent/CN110997662B/zh not_active Expired - Fee Related
- 2018-08-20 CA CA3073333A patent/CA3073333A1/en active Pending
-
2020
- 2020-03-20 ZA ZA2020/01780A patent/ZA202001780B/en unknown
-
2022
- 2022-03-14 US US17/693,527 patent/US20220306588A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531526A5 (enExample) | ||
| RU2506256C2 (ru) | Лиганды для визуализации иннервации сердца | |
| JP2022524914A5 (enExample) | ||
| JP2020528922A5 (enExample) | ||
| CA2324418A1 (en) | Novel opiate compounds, methods of making and methods of use | |
| JP2019104748A5 (enExample) | ||
| RU99128073A (ru) | Замещенные 2-(2,6-диоксопиперидин-3-ил)-фталимиды и -1-оксоизоиндолины и способ снижения уровней фноа | |
| KR830007624A (ko) | 헤테로 사이클릭 화합물의 제조방법 | |
| JP2023504542A5 (enExample) | ||
| CA2457054A1 (en) | Activator of peroxisome proliferator-activated receptor .delta. | |
| RU2008152087A (ru) | Макроциклические оксимильные ингибиторы протеазы гепатита | |
| RU2012143212A (ru) | Способ лечения артрита | |
| ES436385A1 (es) | Procedimiento para la preparacion de compuestos derivados deanilidas. | |
| JP2004525117A5 (enExample) | ||
| RU2007131274A (ru) | Замещенные пиразолопиридины, композиции, содержащие их, способ получения и применение | |
| KR870011129A (ko) | 디스타마이신 a 동족체 및 이의 제조방법 | |
| JP2009536221A5 (enExample) | ||
| JP2002531564A5 (enExample) | ||
| GB1046506A (en) | Guanidine compounds and process for their manufacture | |
| RU2009125439A (ru) | Комбинация ингибитора гда и антиметаболита | |
| EP0092158A3 (en) | Thiazolidine compound and fungicidal composition containing it | |
| JP2020504184A5 (enExample) | ||
| MX2024008480A (es) | Compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2). | |
| JP2021528421A5 (enExample) | ||
| JP2025160251A5 (enExample) |